Issue navigation
Volume 191, Issue 2, August 2024
Original Research
Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies
European Journal of Endocrinology, Volume 191, Issue 2, August 2024, Pages 117–125, https://doi.org/10.1093/ejendo/lvae086
Thyroid hormone levels in children with Prader–Willi syndrome: a randomized controlled growth hormone trial and 10-year growth hormone study
European Journal of Endocrinology, Volume 191, Issue 2, August 2024, Pages 126–133, https://doi.org/10.1093/ejendo/lvae088
European survey of diagnosis and management of the polycystic ovary syndrome: full report on the ESE PCOS Special Interest Group's 2023 Questionnaire
European Journal of Endocrinology, Volume 191, Issue 2, August 2024, Pages 134–143, https://doi.org/10.1093/ejendo/lvae085
Insight into the role of TXNRD2 in steroidogenesis through a novel homozygous TXNRD2 splice variant
European Journal of Endocrinology, Volume 191, Issue 2, August 2024, Pages 144–155, https://doi.org/10.1093/ejendo/lvae090
Metabolically healthy obesity in adults with X-linked hypophosphatemia
European Journal of Endocrinology, Volume 191, Issue 2, August 2024, Pages 156–165, https://doi.org/10.1093/ejendo/lvae089
Prevalence of drugs used for chronic conditions after diagnosis of thyroid cancer: a register-based cohort study
European Journal of Endocrinology, Volume 191, Issue 2, August 2024, Pages 166–174, https://doi.org/10.1093/ejendo/lvae092
Uterine changes in transgender men receiving testosterone therapy
European Journal of Endocrinology, Volume 191, Issue 2, August 2024, Pages 175–182, https://doi.org/10.1093/ejendo/lvae096
Impact of peripheral thyroid hormone balance on liver fat: insights from the NutriAct trial
European Journal of Endocrinology, Volume 191, Issue 2, August 2024, Pages 183–191, https://doi.org/10.1093/ejendo/lvae093
The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial
European Journal of Endocrinology, Volume 191, Issue 2, August 2024, Pages 192–203, https://doi.org/10.1093/ejendo/lvae095
Plasma 21-deoxycortisone: a sensitive additive tool in 21-hydroxylase deficiency in newborns
European Journal of Endocrinology, Volume 191, Issue 2, August 2024, Pages 204–210, https://doi.org/10.1093/ejendo/lvae062
Uncovering the shared genetic components of thyroid disorders and reproductive health
European Journal of Endocrinology, Volume 191, Issue 2, August 2024, Pages 211–222, https://doi.org/10.1093/ejendo/lvae094
Endogenous Cushing's syndrome and cancer risk
European Journal of Endocrinology, Volume 191, Issue 2, August 2024, Pages 223–231, https://doi.org/10.1093/ejendo/lvae098
Prevalence and outcome of secondary hypogonadism in male patients with Cushing's syndrome and mild autonomous cortisol secretion
European Journal of Endocrinology, Volume 191, Issue 2, August 2024, Pages 232–240, https://doi.org/10.1093/ejendo/lvae097
Saline suppression testing-induced hypocalcemia and implications for clinical interpretations
European Journal of Endocrinology, Volume 191, Issue 2, August 2024, Pages 241–250, https://doi.org/10.1093/ejendo/lvae099
BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort study
European Journal of Endocrinology, Volume 191, Issue 2, August 2024, Pages 251–261, https://doi.org/10.1093/ejendo/lvae091
Associations between thyroid function, thyroid diseases, and primary aldosteronism
European Journal of Endocrinology, Volume 191, Issue 2, August 2024, Pages 262–270, https://doi.org/10.1093/ejendo/lvae087
Brief Report
Hypothyroidism due to biallelic variants in IYD: description of 4 families and a novel variant
European Journal of Endocrinology, Volume 191, Issue 2, August 2024, Pages K5–K9, https://doi.org/10.1093/ejendo/lvae100
